Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.26+0.09 (+0.88%)
Close on Nov 11, 2026Market cap $170.12MP/E –Yield –
Sutro Biopharma total assets
Total assets on the balance sheet at the end of each period.
Sutro Biopharma's total assets was $194.46M at Jun 30, 2026. For fiscal 2025 it was $173.83M, down 55.1% from the year before. The highest annual figure on record is $470.74M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.83M | -55.1% |
| FY2024 | Dec 31, 2024 | $387.21M | -17.7% |
| FY2023 | Dec 31, 2023 | $470.74M | +15.7% |
| FY2022 | Dec 31, 2022 | $406.94M | +19.2% |
| FY2021 | Dec 31, 2021 | $341.41M | -13.4% |
| FY2020 | Dec 31, 2020 | $394.11M | +152.0% |
| FY2019 | Dec 31, 2019 | $156.37M | -29.9% |
| FY2018 | Dec 31, 2018 | $223.14M | +447.3% |
| FY2017 | Dec 31, 2017 | $40.77M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $194.46M | -25.9% |
| Q1 FY2026 | Mar 31, 2026 | $241.99M | -24.7% |
| Q4 FY2025 | Dec 31, 2025 | $173.83M | -55.1% |
| Q3 FY2025 | Sep 30, 2025 | $209.66M | -53.6% |
| Q2 FY2025 | Jun 30, 2025 | $262.36M | -46.4% |
| Q1 FY2025 | Mar 31, 2025 | $321.43M | -20.3% |
| Q4 FY2024 | Dec 31, 2024 | $387.21M | -17.7% |
| Q3 FY2024 | Sep 30, 2024 | $451.83M | +4.7% |
| Q2 FY2024 | Jun 30, 2024 | $489.04M | +5.2% |
| Q1 FY2024 | Mar 31, 2024 | $403.40M | +12.7% |
| Q4 FY2023 | Dec 31, 2023 | $470.74M | +15.7% |
| Q3 FY2023 | Sep 30, 2023 | $431.73M | +7.7% |
| Q2 FY2023 | Jun 30, 2023 | $464.90M | +20.6% |
| Q1 FY2023 | Mar 31, 2023 | $358.02M | +17.9% |
| Q4 FY2022 | Dec 31, 2022 | $406.94M | +19.2% |
| Q3 FY2022 | Sep 30, 2022 | $400.70M | +7.9% |
| Q2 FY2022 | Jun 30, 2022 | $385.62M | +7.2% |
| Q1 FY2022 | Mar 31, 2022 | $303.68M | -15.3% |
| Q4 FY2021 | Dec 31, 2021 | $341.41M | -13.4% |
| Q3 FY2021 | Sep 30, 2021 | $371.47M | +20.9% |
| Q2 FY2021 | Jun 30, 2021 | $359.79M | +29.6% |
| Q1 FY2021 | Mar 31, 2021 | $358.53M | +133.0% |
| Q4 FY2020 | Dec 31, 2020 | $394.11M | +152.0% |
| Q3 FY2020 | Sep 30, 2020 | $307.24M | +79.0% |
| Q2 FY2020 | Jun 30, 2020 | $277.54M | +47.0% |
| Q1 FY2020 | Mar 31, 2020 | $153.88M | -24.0% |
| Q4 FY2019 | Dec 31, 2019 | $156.37M | -29.9% |
| Q3 FY2019 | Sep 30, 2019 | $171.68M | +18.4% |
| Q2 FY2019 | Jun 30, 2019 | $188.81M | +363.1% |
| Q1 FY2019 | Mar 31, 2019 | $202.46M | – |
| Q4 FY2018 | Dec 31, 2018 | $223.14M | – |
| Q3 FY2018 | Sep 30, 2018 | $145.03M | – |
| Q4 FY2017 | Dec 31, 2017 | $40.77M | – |
See a number that looks wrong?